Oral HDV GLP1
Alternative Names: Oral HDV-GLP-1Latest Information Update: 28 Mar 2025
At a glance
- Originator Diasome Pharmaceuticals
- Class Antihyperglycaemics; Obesity therapies
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Obesity; Type 2 diabetes mellitus
Most Recent Events
- 28 Mar 2025 Preclinical trials in Obesity in USA (PO), prior to March 2025 (Diasome Pharmaceuticals pipeline, March 2025)
- 28 Mar 2025 Preclinical trials in Type 2 diabetes mellitus in USA (PO), prior to March 2025 (Diasome Pharmaceuticals pipeline, March 2025)